Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Sabine Vogler, Maximilian Salcher-Konrad & Katharina Habimana. (2023) Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?. Expert Review of Pharmacoeconomics & Outcomes Research 23:8, pages 867-878.
Read now
Read now
Konstantin Tachkov, Alexandra Savova, Manoela Manova & Guenka Petrova. (2023) Tackling reimbursement challenges to fair access to medicines – introduction to the topic. Expert Review of Pharmacoeconomics & Outcomes Research 23:6, pages 597-606.
Read now
Read now
Sabine Vogler. (2021) Can we achieve affordable cancer medicine prices? Developing a pathway for change. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 321-325.
Read now
Read now
Joon Seok Bang & Jong Hyuk Lee. (2021) The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways. Expert Opinion on Orphan Drugs 9:4, pages 105-112.
Read now
Read now
Zoltán Kaló, Zoltán Vokó, Kasem S Akhras & Panos Kanavos. (2016) Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries. Expert Review of Pharmacoeconomics & Outcomes Research 16:1, pages 15-16.
Read now
Read now
João L. Carapinha. (2016) Comment on the implications of external price referencing of pharmaceuticals in Middle East countries. Expert Review of Pharmacoeconomics & Outcomes Research 16:1, pages 11-14.
Read now
Read now
Articles from other publishers (21)
Fatemeh Babaie, Mohammad Hossein Motevalli, Gholamhossein Mehralian, Farzad Peiravian & Nazila Yousefi. (2023) How does external reference pricing work in developing countries: evidence from Iran. Frontiers in Pharmacology 14.
Crossref
Crossref
Ahmad Fasseeh, Baher ElEzbawy, Wessam Adly, Rawda ElShahawy, Mohsen George, Sherif Abaza, Amr ElShalakani & Zoltán Kaló. (2022) Healthcare financing in Egypt: a systematic literature review.. Journal of the Egyptian Public Health Association 97:1.
Crossref
Crossref
Augustina Koduah, Leonard Baatiema, Anna Cronin de Chavez, Anthony Danso-Appiah, Irene A. Kretchy, Irene Akua Agyepong, Natalie King, Timothy Ensor & Tolib Mirzoev. (2022) Implementation of medicines pricing policies in sub-Saharan Africa: systematic review. Systematic Reviews 11:1.
Crossref
Crossref
Emad Almomani, Eman A. Hammad, Raeda AlQutob, Khawla Abu Hammour, Emad Al-Sharu, Muien Abu-Shaer, Ibrahim Alabbadi & Zoltán Kaló. (2022) Capacity Building for Health Technology Assessment in Jordan: Institutionalization and Its Use in Pricing and Reimbursement Decisions. Value in Health Regional Issues 32, pages 47-53.
Crossref
Crossref
Hoda Ibrahim Rizk, Monira Mahmoud Elkholy, Abeer Abdou Barakat, Raghda Mostafa Mostafa Elsayed & Shaimaa A. M. Abd El Fatah. (2021) Perspectives of pharmaceutical stakeholders on determinants of medicines accessibility at the primary care level. Journal of the Egyptian Public Health Association 96:1.
Crossref
Crossref
Sabine Vogler, Peter Schneider & Lena Lepuschütz. (2020) Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Crossref
Panos Kanavos, Bregtje W. Kamphuis, Anna-Maria Fontrier, Georgia Colville Parkin, Shadi Saleh & Kasem S. Akhras. (2020) Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?. Health Policy 124:12, pages 1297-1309.
Crossref
Crossref
Sungju Kim & Jong Hyuk Lee. (2020) Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction. Healthcare 8:3, pages 233.
Crossref
Crossref
Jennifer Gill, Anna-Maria Fontrier, Dionysis Kyriopoulos & Panos Kanavos. (2019) Variations in external reference pricing implementation: does it matter for public policy?. The European Journal of Health Economics 20:9, pages 1375-1397.
Crossref
Crossref
Nada Abdel Rida, Mohamed Izham Mohamed Ibrahim & Zaheer‐Ud‐Din Babar. (2019) Pharmaceutical pricing policies in Qatar and Lebanon: narrative review and document analysis. Journal of Pharmaceutical Health Services Research 10:3, pages 277-287.
Crossref
Crossref
Anke-Peggy Holtorf, Fotini Gialama, Kalman Emry Wijaya & Zoltán Kaló. (2019) External Reference Pricing for Pharmaceuticals—A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage. Value in Health Regional Issues 19, pages 122-131.
Crossref
Crossref
Sabine Vogler, Peter Schneider & Nina Zimmermann. (2019) Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing. PharmacoEconomics - Open 3:3, pages 303-309.
Crossref
Crossref
Peter Schneider & Sabine Vogler. 2019. Medicine Price Surveys, Analyses and Comparisons. Medicine Price Surveys, Analyses and Comparisons
345
368
.
Sergio I. Prada, Victoria E. Soto, Tatiana S. Andia, Claudia P. Vaca, Álvaro A. Morales, Sergio R. Márquez & Alejandro Gaviria. (2018) Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
Christiane Maskineh & Soumana C. Nasser. (2018) Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook. Value in Health Regional Issues 16, pages 33-38.
Crossref
Crossref
Marcell Csanádi, Zoltán Kaló, Christian P.J. Prins, Eszter Grélinger, Anna Menczelné Kiss, Frank-Ulrich Fricke, Leoš Fuksa, Tomas Tesar, Manoela Manova, László Lorenzovici, Zoltán Vokó & Louis P. Garrison. (2018) The implications of external price referencing on pharmaceutical list prices in Europe. Health Policy and Technology 7:3, pages 243-250.
Crossref
Crossref
Nada Abdel Rida & Mohamed Izham Mohamed Ibrahim. 2018. Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries. Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries
111
128
.
Nada Abdel Rida, Mohamed Izham Mohamed Ibrahim, Zaheer-Ud-Din Babar & Yaw Owusu. (2017) A systematic review of pharmaceutical pricing policies in developing countries. Journal of Pharmaceutical Health Services Research 8:4, pages 213-226.
Crossref
Crossref
Ranya Hassan, Hafiz Alam Sher, Rabia Khokhar & Rabia Hussain. 2017. Pharmaceutical Policy in Countries with Developing Healthcare Systems. Pharmaceutical Policy in Countries with Developing Healthcare Systems
365
379
.
Péter Elek, Eszter Takács, Gergő Merész & Zoltán Kaló. (2016) Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries. Health Policy and Planning, pages czw133.
Crossref
Crossref
Omneya Mohamed & David H. Kreling. (2016) The Impact of a Pricing Policy Change on Retail Prices of Medicines in Egypt. Value in Health Regional Issues 10, pages 14-18.
Crossref
Crossref